Suzette Kox Named Secretary General Of International Generic And Biosimilar Medicines Association

The Geneva-based International Generic and Biosimilar medicines Association (IGBA) has named industry veteran Suzette Kox as secretary general.

Her main role will be to coordinate the association’s efforts to expand its outreach. Kox has a long history of involvement in biosimilars, and came from several years in a senior role in the Biosimilar Medicines Group at Medicines for Europe, according to sources.

In a press release, Kox mentioned universal health coverage, intellectual property rights, drug shortages and supply chain security as priorities.

The IGBA is an association made up of the following associations:

  • Association for Accessible Medicines (AAM-USA)
  • Canadian Generic Pharmaceutical Association (CGPA-Canada)
  • Generic & Biosimilar Medicines Southern Africa (GBM-Southern Africa)
  • Japan Generic Medicines Association (JGA-Japan)
  • Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordan)
  • Indian Pharmaceutical Alliance (IPA-India)
  • Medicines for Europe (Europe)
  • Taiwan Generic Pharmaceutical Association (TGPA-Taiwan)
  • In addition, the generic medicines associations of Australia, Mexico, Malaysia, Saudi Arabia, and Brazil are Associate Members

The full press release is reprinted below:

Suzette Kox nominated as Secretary General of the International Generic and Biosimilar medicines Association

For Immediate Release

Geneva, February 2019

IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announces today the nomination of Suzette Kox as Secretary General of the Association.

Her main role is to coordinate the IGBA activities as the Association continues to expand its outreach relevant to its mission, priorities and operations.

Suzette brings with her 28 years of substantial contribution to the roles and activities of the European and international generic and biosimilar industry trade bodies.

I am thrilled about the newly strengthened IGBA, which is needed to ensure that regulatory & science, trade & intellectual property as well as legal developments take into account the crucial role of our industries for the benefit of patients worldwide, as well as the national healthcare systems”, said Jim Keon, President of the Canadian Generic Pharmaceutical Association and Biosimilars Canada, who has taken over the position of IGBA Chair for 2019 from David Gaugh, Senior Vice-President for Sciences and Regulatory Affairs of the U.S. Association for Accessible Medicines.

“I very much look forward to continuing to contribute to increased and sustainable patient access to high quality medicines worldwide, as well as to the UN Member States Universal Healthcare Coverage (UHC) vision by 2030”, commented Suzette Kox. “The long-term sustainability of our industries and balanced intellectual property systems are key to delivering on competition in the pharmaceutical sector, addressing the concerns of drug shortages and supply-chain security, as well as supporting the international harmonisation of standards through ICH”, she added.

About IGBA

The International Generic and Biosimilar medicines Association (IGBA) was founded to strengthen cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients around the world have access to high quality, pro-competitive medicines. For more details regarding IGBA and its member associations, see the IGBA website at:


Image Credits: International Generic and Biosimilar medicines Association.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.